Aziz Kabeer 4
4 · AN2 Therapeutics, Inc. · Filed Feb 23, 2026
Research Summary
AI-generated summary of this filing
AN2 Therapeutics Director Aziz Kabeer Receives Award of 20,400 Shares
What Happened Aziz Kabeer, a director of AN2 Therapeutics, was granted a derivative award of 20,400 shares on 2026-02-20. The award was recorded at $0.00 (no cash exchanged) and is reported as a derivative/award rather than an open-market purchase or sale. The filing shows the award will vest subject to continued service.
Key Details
- Transaction date: 2026-02-20; Form 4 filed 2026-02-23. No late-filing flag indicated in the filing.
- Amount granted: 20,400 shares (derivative award) at $0.00; immediate value reported as $0.
- Vesting: Per footnote, the option shares vest on 2027-02-20, contingent on continuous service.
- Shares owned after transaction: Not specified in the filing.
- Transaction type code: A (Grant/Award).
Context This was a compensatory award of derivative securities (option shares or similar) that do not represent immediately tradable common shares until they vest and any exercise conditions are met. Such awards are commonly used for compensation or retention; they are not an open-market buy or sale and do not reflect an immediate change in public float.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-02-20+20,400→ 20,400 totalExercise: $1.04Exp: 2036-02-19→ Common Stock (20,400 underlying)
Footnotes (1)
- [F1]The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date.